Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
ApexOnco Front Page
Recent articles
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
Daraxonrasib scores a plenary session late-breaker.
The disclosure comes as another of Arcus's TIGIT trials flops.
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
First-in-human results prompt a biomarker-defined approach for CID-078.
